Artiva Biotherapeutics

ARTV

Börsenwert 286 Mio. $

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), a population similar to that being studied in the Phase 3 registrational trial Live webcast on Monday, November 9, 2026 at 8:15 am EST to review Artiva's presentations, including an in-depth analysis of data from at least 10 patients with refractory RA who have at least six months of follow-up and would meet key eligibility criteria for the Phase 3 registrational trial SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK® program and a registry analysis of the high unmet medical need in refractory RA. Artiva will host a live webcast on Monday, November 9, 2026, at 8:15 am EST to review its ACR presentations and updated clinical data from at least 20 patients with refractory RA who have at least six months of follow-up.

Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren's Disease (ISSjD 2026)

SAN DIEGO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that updated clinical data will be delivered in an oral presentation at the 17th International Symposium on Sjögren's Disease (ISSjD 2026), taking place September 29th – October 2nd at the Cité Internationale Universitaire de Paris: Abstract Title: AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy, Combined withRituximab Generates Robust Efficacy Responses in 11 Patients with Sjögren Disease Presenting Author: Guillermo J.

SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:00 am EDT.

Updated clinical data expected in the second half of 2026 from at least 20 patients with refractory rheumatoid arthritis (RA) treated with AlloNK and rituximab in the ongoing company-sponsored Phase 2a basket trial, each with at least six months of follow-up, including at least 10 patients who would meet key eligibility criteria for the Phase 3 registrational trial in refractory RA Updated clinical data expected in the second half of 2026 from at least 10 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc), each with at least six months of follow-up Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK® plus rituximab versus rituximab alone in approximately 150 patients with refractory RA, with further updates on site activation and enrollment initiation expected in the second half of 2026 SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today provided an update on anticipated data disclosures and development milestones for its lead program, AlloNK® (also known as AB-101), through year-end 2026.

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that management will participate at the following investor conferences: 2026 Cantor Global Healthcare Conference – live fireside chat on Wednesday, September 9, 2026 at 10:20 am EDT H.C.

Clinical, safety and translational data presented at EULAR 2026 reinforced AlloNK®'s potential to drive deep B-cell depletion and meaningful clinical activity, with a tolerability profile supportive of outpatient administration U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to AlloNK plus rituximab for refractory rheumatoid arthritis (RA) Initiating Phase 3 registrational randomized controlled trial evaluating AlloNK plus rituximab versus rituximab alone in approximately 150 refractory RA patients in the second half of 2026 Strong balance sheet with cash, cash equivalents and investments of $349.4 million as of June 30, 2026, expected to fund operations into 2029 SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced financial results for the second quarter ended June 30, 2026, and highlighted recent progress. “The second quarter was transformative for Artiva.

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that the Compensation Committee of its Board of Directors approved new employee inducement grants covering an aggregate of 288,800 restricted stock units (the “Inducement Grants”) for 17 new employees.

Here is how Artiva Biotherapeutics, Inc. (ARTV) and Climb Bio, Inc. (CLYM) have performed compared to their sector so far this year.

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT.